News | September 18, 2024
Lupin inks licensing agreement with Takeda to commercialize Vonoprazan
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
The pooled prevalence of GERD in the Indian population is 15.6 %
Acquisition to expand Lilly's immunology pipeline with oral integrin therapies
NCIL was listed at Rs. 171 at an upper circuit premium of 90% over the fixed price band of Rs. 90
SYNERGY-NASH results were presented at the European Association for the Study of the Liver Congress 2024 and simultaneously published in The New England Journal of Medicine
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
The 200 bedded hospital owned & operated by Alexis
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
This acquisition marks Max Healthcare's entry into Lucknow
Subscribe To Our Newsletter & Stay Updated
